Inspection Fees For Drug, Ingredient Manufacturers Could End Up In PDUFA, Sen. Harkin Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The chairman of the HELP committee also open to a track and trace mechanism for drugs and their ingredients and denying U.S. entry to drugs from facilities that deny entry to U.S. inspectors.
You may also be interested in...
Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed
At user fee hearing, PhRMA’s Wheadon counters questions from Rep. Dingell, saying FDA already is receiving resources to conduct GMP inspections outside the U.S.
USP To Bring Global Perspective To Track And Trace Discussion
The U.S. Pharmacopeial Convention released a framework Jan. 4 for instituting supply chain security measures and plans a May workshop with speakers from other countries to discuss their programs for tracking drug components and products through distribution channels.